Daraxonrasib Neden Bu Kadar Önemli? | Pankreas Kanserinde KRAS Devrimi mi?

One of the most talked-about topics in pancreatic cancer recently has been new drugs targeting KRAS mutations. In particular, the data released regarding Daraxonrasib has raised the question of whether this could mark the beginning of a new era in this disease, which has had limited treatment options for many years. So, what is KRAS? KRAS is a key pathway in pancreatic cancer cells that regulates growth, proliferation, and survival under stress. Approximately 90-95% of classic pancreatic cancer cases today have KRAS mutations. Therefore, KRAS has been central to pancreatic cancer research for many years. In this video, we explore the following questions: • What is a KRAS mutation? • Why is it so common in pancreatic cancer? • Is KRAS the cause of pancreatic cancer or part of the cancer development process? • How does Daraxonrasib work? • What do the results obtained in patients with metastatic pancreatic cancer mean? • Could this drug truly be a turning point? • When will patients in Türkiye and around the world have access to these treatments? • In which patients can genetic tests be helpful? Every new development in pancreatic cancer treatment requires cautious optimism. However, the fact that KRAS, which was considered "untargetable" for years, is now beginning to be included among treatment options is seen as a significant development in oncology. Every day we gain also means additional time for medicine to discover new treatments. In this video, we evaluate the biology of KRAS and current data on Daraxonrasib within a scientific framework. #PancreaticCancer #KRAS #Daraxonrasib #PancreaticCancerTreatment #KRASMutation #Oncology #MertErkan #CancerResearch